ArticleRSC advances2026
Nanozymes based on functionalized iridium oxide-modified gold nanoparticles for combination therapy.
Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Combination therapy has become the trend in cancer treatments. Iridium oxide-based nanoparticles have shown potential for application in tumour therapy due to their excellent photophysical-chemical and hydrogen peroxide-like enzymatic activities. However, during the practical application of functionalized iridium oxide, it was observed that a high-power near-infrared laser (NIR) is required to achieve better results. The excellent photothermal conversion efficiency of gold nanoparticles has been widely verified. Based on these facts, nanozymes based on functionalized iridium oxide-modified gold nanoparticles (PIrS@Au) were developed. PIrS@Au with good photothermal conversion efficiency, photochemical activity, catalase-like activity and biocompatibility could be effectively taken up by HeLa and HepG2 cells.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.